AMGN - Amgen Inc. Summary, Stock Quote and News

233.84 1.02 (0.44%)

Data as of Dec 11, 2019

Prev. Close 232.82
Price Open 231.92
Volume 1,494,839
Day's Range 231.52 - 235.11
52 Wk Range 166.3 - 235.8
50 Day Moving Avg. 214.76
PE Ratio 17.960061
Shares Outstanding 594.18M
Market Cap 138.94B

Trade AMGN stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
12/09/19	Argus Research	Maintains	Buy	265.0
11/12/19	SunTrust Robinson Humphrey	Initiates Coverage On	Buy	256.0
11/05/19	Cantor Fitzgerald	Upgrades	NeutralOverweight	255.0

Janssen Announces Results From Phase 3 CANDOR Study; DARZALEX Regimen Showed 'Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma' Benzinga NewsdeskTue, 10 Dec 2019 08:00:31 -0500
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Shanthi RexalineTue, 10 Dec 2019 07:56:02 -0500
Amgen To Present Data From Phase 3 CANDOR Study Combining KYPROLIS And DARZALEX At American Society Of Hematology Annual Meeting Benzinga NewsdeskTue, 10 Dec 2019 07:34:58 -0500
9 Most Overbought Stocks In The S&P 500 Wayne DugganMon, 09 Dec 2019 10:35:46 -0500
Argus Research Maintains Buy on Amgen, Raises Price Target to $265 Benzinga_NewsdeskMon, 09 Dec 2019 08:49:00 -0500
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Shanthi RexalineSat, 07 Dec 2019 08:35:07 -0500
BeiGene 8-K Shows Co., Amgen Entered Amendment To Share Purchase Deal To Allow Amgen To Subscribe For, Co. To Allot, Issue To Amgen Added Ordinary Shares In Amount Necessary For Amgent To Hold 20.5% Of Outstanding Share Capital Benzinga NewsdeskFri, 06 Dec 2019 16:10:57 -0500
FDA Earlier Approved Amgen's Avsola For Injection, For Intravenous Use; Avsola Is Biosimilar To Remicade Benzinga NewsdeskFri, 06 Dec 2019 11:59:30 -0500
Cramer Weighs In On Biogen, Caterpillar And More Craig JonesTue, 03 Dec 2019 11:22:46 -0500
U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada Benzinga NewsdeskMon, 02 Dec 2019 16:09:29 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting PRNewswire19 hours ago
Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease PRNewswire1 day ago
Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub PRNewswire1 day ago
FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab) PRNewswire4 days ago
Abarca, Amgen Enter Outcome-Based Agreement For Enbrel PRNewswireDec 03, 2019
Amgen Announces Data Being Presented At ASH 2019 PRNewswireDec 02, 2019
Thinking about trading options or stock in Amgen, The Medicines Company, Netflix, NVIDIA, or Charles Schwab? PRNewswireNov 26, 2019
Amgen Completes Acquisition Of Otezla® (apremilast) PRNewswireNov 21, 2019
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company Business WireNov 20, 2019
New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function Globe NewswireNov 18, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Biotech ETFs Hit New Highs on Deal Activities Zacks17 hours ago
Healthpeak Amends & Extends Lease With Amgen in San Francisco Zacks18 hours ago
Healthpeak in lease amendment, extension with Amgen Seeking Alpha1 day ago
HDV: Why Investing In High Dividend ETF Is Not Worthwhile Seeking Alpha1 day ago
Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar Zacks1 day ago
Netflix, Cisco And Chewy On The Marquee (Stocks To Watch Podcast) Seeking Alpha2 days ago
Roche candidates show promising action in treatment-resistant NHL Seeking Alpha3 days ago
Stocks To Watch: Netflix, Cisco And Chewy On The Marquee Seeking Alpha3 days ago
BeiGene agrees to allow Amgen to accumulate additional shares Seeking Alpha4 days ago
FDA OKs Amgen's Remicade biosimilar Seeking Alpha4 days ago
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q3 2019	EST	Actual	Surprise
EPS:	3.520	3.660	0.1400
Rev:	5.64B	5.74B	97.00M

Q4 2019	EST	Actual	Surprise
EPS:	Expected 2020-01-28
Rev:	Expected 2020-01-28

Company Profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Visit company website

Brokerage Center

Compare All Online Brokerages

Market Overview

Amgen Inc. AMGN:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Amgen Inc. AMGN:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners